MarketPulse
M

$MAZE

5 articles found
3 positive
0 negative
2 neutral
The Motley FoolThe Motley Fool··Sarah Sidlow

Maze Therapeutics CSBO Sells $190K in Stock Despite Strong Trial Data

Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares for $190,000 under a pre-planned trading agreement, concurrent with positive phase 2 trial results.
MAZEclinical-stage biotechprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Maze Therapeutics Raises $150M to Fund Late-Stage Drug Pipeline Through 2029

Maze Therapeutics prices $150M offering at $23.50/share, securing funding through 2029 for kidney disease and PKU programs.
MAZEclinical developmentcapital raise
The Motley FoolThe Motley Fool··Robert Izquierdo

Maze CMO Dumps Entire Stock Position as Biotech Faces Clinical Uncertainty

Maze Therapeutics CMO Harold Bernstein sold 15,000 shares (~$442K) via pre-planned trading arrangement. Retains 237K options amid clinical-stage biotech challenges.
MAZEFDA approvalkidney disease
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics President Liquidates Full Position Ahead of Q4 Earnings

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.
MAZEclinical-stage biotechearnings report
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics CMO Completes Share Divestiture Amid Positive Clinical Momentum

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.
MAZEIPOclinical trials